Clinical Assessment of Complementary Treatment With Qishen Yiqi Dripping Pills on Ischemic Heart Failure

Overview

CACT-IHF aims to evaluate the clinical efficacy and safety of Qishen Yiqi Dripping Pills in treating ischemic heart failure. Meeting the diagnosis, inclusion and exclusion criteria, the study plans to recruit 640 cases from 35 upper class hospitals in China, who are divided into two groups (treatment and control group) by central randomization service. The treatment group will be administrated with one bag of Qishen Yiqi Dripping Pills (0.52g/bag) three times a day in addition to standardized western medications. Whereas the control group will be given one bag of Qishen Yiqi Dripping Pills dummy (0.52g/bag) three times a day in addition to standardized western medications. Efficacy indicators include primary indicator (6 minute walk test) and secondary indicators: composite endpoint consisting of all-cause death, emergency/re-admission to hospital due to HF, frequency of re-admission due to cardiovascular disease, acute coronary syndrome, severe arrhythmia, cardiac shock, revascularization, stroke, pulmonary embolism and peripheral vascular incidences, etc.; Brain Natriuretic Peptide; echocardiography; cardiothoracic ratio; NYHA cardiac function classification; Minnesota life quality scale; scores from the four traditional chinese medicine (TCM) diagnostic methods). Other indicators include blood cholesterol, triglyceride, high density cholesterol and low density cholesterol. Safety indicators include blood pressure, heart rate, blood and urine routine tests, liver and renal function tests, serum electrolytes, electrocardiogram and adverse events. All of the patients will receive interventional drug treatment for 6 months. Follow up is needed on the 1st, 3rd, 6th, 9th, 12th month after recruitment. All patients will be followed up until the end of study (Refers to the 12th month of the last case recruited into the study).

Full Title of Study: “Clinical Assessment of Complementary Treatment With Qishen Yiqi Dripping Pills on Ischemic Heart Failure (CACT-IHF) A Randomized, Double-blind, Multicenter, Placebo-controlled Trial”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: September 2013

Interventions

  • Drug: Qishen Yiqi Dripping Pills
    • One packet of Qishen Yiqi Dripping Pills (0.52g) will be given three times a day in addition to regular western medications for the first 6 months, and regular western medications only for the subsequent 6 months.
  • Drug: Qishen Yiqi dripping pills dummy
    • One packet of Qishen Yiqi Dripping Pills dummy (0.52g) will be given three times a day in addition to regular western medications for the first 6 months, and regular western medications only for the subsequent 6 months.

Arms, Groups and Cohorts

  • Placebo Comparator: Qishen Yiqi dripping pills dummy
  • Experimental: Qishen Yiqi Dripping Pills

Clinical Trial Outcome Measures

Primary Measures

  • 6MWT distance
    • Time Frame: 0 month
  • 6MWT
    • Time Frame: 3rd month
  • 6MWT
    • Time Frame: 6th month

Secondary Measures

  • Composite endpoint
    • Time Frame: 1st,3rd,6th,9th,12th month
    • all-cause death, frequency of emergency/re-admission to hospital due to HF, frequency of re-admission due to cardiovascular disease, acute coronary syndrome, severe arrhythmia, cardiac shock, revascularization, stroke, pulmonary embolism and peripheral vascular incidences, etc.
  • Brain natriuretic peptide (BNP)
    • Time Frame: 0,6th month
  • Echocardiography
    • Time Frame: 0,6th month
  • Cardiothoracic Ratio(CR)
    • Time Frame: 0,6th month
  • Cardiac function classification, NYHA
    • Time Frame: 0,1st,3rd,6th,9th,12th month
  • Minnesota life quality scale
    • Time Frame: 0,1st,3rd,6th,9th,12th month
  • Scores from the four TCM diagnostic methods
    • Time Frame: 0,1st,3rd,6th,9th,12th month
  • blood and urine routine tests,liver and renal function tests,serum electrolytes,electrocardiogram (ECG)
    • Time Frame: 0,3rd,6thmonth

Participating in This Clinical Trial

Inclusion Criteria

  • Age 40 to 79 – Patients with ischemic heart failure: – LVEF less than or equal to 45% measured by echocardiography in modified Simpson method – History of prior myocardial infarction with or without percutaneous coronary intervention (PCI) or/and coronary artery bypass grafting (CABG); – Coronary angiography (CAG) or coronary CTA shows more than or equal to 50% stenosis in at least one of the main coronary arteries with or without revascularization, of which the researcher thinks that it is closely related to heart failure; – With or without dyspnea, fatigue and fluid retention (edema) etc. – History of heart failure or present with heart failure symptoms for at least 3 months; – New York Heart Association (NYHA) Class II to IV; – Submitted informed consent Exclusion Criteria:

  • Acute heart failure or acute exacerbation of chronic heart failure – Those who have one of the following diseases: – Acute coronary syndrome within 30 days – Revascularization therapy within 6 months – Uncontrolled hypertension with systolic pressure more than or equal to 180mmHg and/or diastolic pressure more than or equal to 110mmHg – Second degree type 2 or worse sinoatrial/atrioventricular block without implantation of pacemaker or uncontrolled malignant cardiac arrhythmia – Dilated cardiomyopathy – Hypertrophic obstructive cardiomyopathy – Myocarditis – Pulmonary artery embolism – Severe valvular heart disease – Pulmonary heart disease – Stroke within 6 months – Cardiac resynchronization therapy – Applied diuretics, cardiotonic agents or vasodilators intravenously within 7 days – Severe endocrine diseases such as hyperthyroidism, etc. – History of malignant tumor – Hemoglobin (HB )≤ 9g/dl – Alanine aminotransferase (ALT) > 2 times the upper limit of normal – Serum creatinine > 265 μmol/L – Mental disorder – Being pregnant, planning for pregnancy or breastfeeding – Suspicious or definite allergy to intervention drugs – Participated in other trials within 2 months – Unable to walk autonomously due to physical disabilities

Gender Eligibility: All

Minimum Age: 40 Years

Maximum Age: 79 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • State Administration of Traditional Chinese Medicine of the People’s Republic of China
  • Provider of Information About this Clinical Study
    • Principal Investigator: Jingyuan Mao, Prof. – First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
  • Overall Official(s)
    • Jingyuan Mao, Dr., Principal Investigator, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
  • Overall Contact(s)
    • Yazhu Hou, Dr., 8622-27432325, mreleven@163.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.